James Weingarten

Partner at Milbank

Speaker

James is an antitrust litigation partner in Milbank’s global competition group. Before joining Milbank in 2024, James was Chief Trial Counsel for the Federal Trade Commission. In that role, James tried some of the government’s most significant antitrust enforcement cases, including both merger and Sherman Act cases. Representative cases at the FTC include: FTC v. Vyera Pharmaceuticals (judgment finding unlawful exclusive dealing resulting in first ever lifetime ban of an individual from the pharmaceutical industry); FTC v. AbbVie, Inc. (judgment finding that Hatch-Waxman litigation constituted unlawful sham litigation, liability affirmed in the 3^rd Circuit); and In re Impax Laboratories, Inc. (administrative decision finding unlawful reverse-payment patent settlement, affirmed in the 5^th Circuit). Before joining the FTC, James was in private practice, where is trial work included trying In re Nexium (full defense verdict for client AstraZeneca in reverse-payment class action, affirmed in 1^st Circuit). Across his career, James has led or been part of teams that brought nearly a dozen cases to verdict or judgment. At Milbank, James represents clients in government investigations and enforcement actions, HSR second requests and class actions and other private litigations.